<DOC>
	<DOCNO>NCT01868061</DOCNO>
	<brief_summary>This randomize , multicenter , double-blind , placebo-controlled , parallel-group study evaluate efficacy safety lebrikizumab participant asthma whose disease remain uncontrolled despite daily treatment inhale corticosteroid ( ICS ) therapy least one second controller medication . Participants randomize 1:1:1 ratio receive double-blind treatment either lebrikizumab ( `` high '' `` low '' ) placebo , administer subcutaneous ( SC ) injection every 4 week 52 week , addition standard-of-care therapy . This follow 52-week double-blind active treatment extension . Participants assign placebo placebo-controlled period trial re-randomized Week 52 receive blind SC lebrikizumab 37.5 milligram ( mg ) 125 mg every 4 week Weeks 53 104 . The anticipated time study treatment 104 week . After study treatment , participant complete 20-week safety follow-up .</brief_summary>
	<brief_title>A Study Lebrikizumab Participants With Uncontrolled Asthma Inhaled Corticosteroids Second Controller Medication</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Asthma diagnosis great equal ( &gt; /= ) 12 month Visit 1 Bronchodilator response Visit 1 , 2 , 3 Prebronchodilator FEV1 40 percent ( % ) 80 % predict Visits 2 3 On ICS therapy total daily dose 5002000 microgram ( mcg ) fluticasone propionate dry powder inhaler ( DPI ) equivalent &gt; /= 6 month prior Visit 1 On eligible second controller medication ( longacting Betaagonist [ LABA ] , leukotriene receptor antagonist [ LTRA ] , longacting muscarinic antagonist [ LAMA ] , theophylline ) 6 month prior Visit 1 Uncontrolled asthma Visit 1 and/or Visit 2 , Visit 3 Chest Xray compute tomography ( CT ) scan within 3 month prior Visit 1 chest Xray screen period ( prior Visit 3 ) confirm absence clinically significant lung disease Demonstrated adherence controller medication screen period History severe allergic reaction anaphylactic reaction biologic agent know hypersensitivity component lebrikizumab injection Maintenance oral corticosteroid therapy within 3 month Visit 1 Treatment systemic ( oral , intravenous [ IV ] , intramuscular [ IM ] ) corticosteroid within 4 week prior Visit 1 screen period Treatment intraarticular corticosteroid within 4 week prior Visit 1 screen period anticipate need intraarticular corticosteroid course study Infection require hospital admission &gt; /=24 hour require treatment IV IM antibiotic within 4 week prior Visit 1 screening ; Upper low respiratory tract infection within 4 week prior Visit 1 screening ; Active parasitic infection Listeria monocytogenes infection within 6 month prior Visit 1 screen Active tuberculosis require treatment within 12 month prior Visit 1 Known immunodeficiency , include , limited , human immunodeficiency virus ( HIV ) infection Evidence acute chronic hepatitis know liver cirrhosis History interstitial lung disease , chronic obstructive pulmonary disease ( COPD ) , clinically significant lung disease asthma Known current malignancy current evaluation potential malignancy Current smoker former smoker history great ( &gt; ) 10 packyears History alcohol drug abuse Past and/or current use antiinterleukin ( IL ) 13 antiIL4/IL13 therapy , include lebrikizumab ; use monoclonal antibody therapy , include omalizumab , within 6 month 5 drug halflives prior Visit 1 ( whichever longer ) screen Initiation change allergen immunotherapy within 3 month prior Visit 1 screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>